324 related articles for article (PubMed ID: 29525824)
21. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series.
Bertz S; Denzinger S; Otto W; Wieland WF; Stoehr R; Hofstaedter F; Hartmann A
Histopathology; 2011 Oct; 59(4):722-32. PubMed ID: 22014053
[TBL] [Abstract][Full Text] [Related]
22. Role of tumor suppressor and angiogenesis markers in prediction of recurrence of non muscle invasive bladder cancer.
Agrawal U; Mishra AK; Salgia P; Verma S; Mohanty NK; Saxena S
Pathol Oncol Res; 2011 Mar; 17(1):91-101. PubMed ID: 20571940
[TBL] [Abstract][Full Text] [Related]
23. Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.
Lin YL; Wang YL; Fu XL; Li WP; Wang YH; Ma JG
Oncotarget; 2016 May; 7(19):28384-92. PubMed ID: 27070091
[TBL] [Abstract][Full Text] [Related]
24. Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.
Breyer J; Gierth M; Shalekenov S; Aziz A; Schäfer J; Burger M; Denzinger S; Hofstädter F; Giedl C; Otto W
World J Urol; 2016 May; 34(5):709-16. PubMed ID: 26394624
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
26. Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance.
López JI; Angulo JC
Int Urol Nephrol; 2009 Dec; 41(4):847-54. PubMed ID: 19283508
[TBL] [Abstract][Full Text] [Related]
27. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
[TBL] [Abstract][Full Text] [Related]
28. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.
Abufaraj M; Shariat SF; Haitel A; Moschini M; Foerster B; Chłosta P; Gust K; Babjuk M; Briganti A; Karakiewicz PI; Albrecht W
Urol Oncol; 2017 May; 35(5):264-271. PubMed ID: 28214283
[TBL] [Abstract][Full Text] [Related]
29. Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival.
Li G; Yu J; Song H; Zhu S; Sun L; Shang Z; Niu Y
BMC Cancer; 2017 Aug; 17(1):530. PubMed ID: 28789622
[TBL] [Abstract][Full Text] [Related]
30. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
33. UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer.
Yang GL; Zhang LH; Bo JJ; Chen HG; Cao M; Liu DM; Huang YR
Med Oncol; 2012 Jun; 29(2):842-7. PubMed ID: 21611839
[TBL] [Abstract][Full Text] [Related]
34. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
[TBL] [Abstract][Full Text] [Related]
35. Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.
Kulac I; Arslankoz S; Netto GJ; Ertoy Baydar D
Virchows Arch; 2018 Jun; 472(6):969-974. PubMed ID: 29368083
[TBL] [Abstract][Full Text] [Related]
36. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
Nonomura N; Nakai Y; Nakayama M; Inoue H; Nishimura K; Hatanaka E; Arima R; Kishimoto T; Miki T; Kuroda H; Okuyama A
Int J Clin Oncol; 2006 Aug; 11(4):297-302. PubMed ID: 16937303
[TBL] [Abstract][Full Text] [Related]
37. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
38. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
Poyet C; Buser L; Roudnicky F; Detmar M; Hermanns T; Mannhard D; Höhn A; Rüschoff J; Zhong Q; Sulser T; Moch H; Wild PJ
J Clin Pathol; 2015 Oct; 68(10):819-24. PubMed ID: 26251520
[TBL] [Abstract][Full Text] [Related]
39. Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.
Han B; Cui D; Jing Y; Hong Y; Xia S
World J Urol; 2012 Dec; 30(6):861-7. PubMed ID: 22238119
[TBL] [Abstract][Full Text] [Related]
40. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.
Liu B; Miyake H; Nishikawa M; Fujisawa M
Urol Oncol; 2015 Mar; 33(3):110.e11-8. PubMed ID: 25262382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
